These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 24480360)
1. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Tranoy-Opalinski I; Legigan T; Barat R; Clarhaut J; Thomas M; Renoux B; Papot S Eur J Med Chem; 2014 Mar; 74():302-13. PubMed ID: 24480360 [TBL] [Abstract][Full Text] [Related]
2. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. Leu YL; Chen CS; Wu YJ; Chern JW J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465 [TBL] [Abstract][Full Text] [Related]
3. A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy. Compain G; Oumata N; Clarhaut J; Péraudeau E; Renoux B; Galons H; Papot S Eur J Med Chem; 2018 Oct; 158():1-6. PubMed ID: 30199702 [TBL] [Abstract][Full Text] [Related]
4. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162 [TBL] [Abstract][Full Text] [Related]
5. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Chen KC; Schmuck K; Tietze LF; Roffler SR Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264 [TBL] [Abstract][Full Text] [Related]
6. Beta-glucuronidase-mediated drug release. de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303 [TBL] [Abstract][Full Text] [Related]
8. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard. Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272 [TBL] [Abstract][Full Text] [Related]
10. A new cyclopamine glucuronide prodrug with improved kinetics of drug release. Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246 [TBL] [Abstract][Full Text] [Related]
11. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy. Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951 [TBL] [Abstract][Full Text] [Related]
12. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605 [TBL] [Abstract][Full Text] [Related]
13. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640 [TBL] [Abstract][Full Text] [Related]
14. Design of self-immolative linkers for tumour-activated prodrug therapy. Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826 [TBL] [Abstract][Full Text] [Related]
15. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. Edupuganti VVSR; Tyndall JDATDA; Gamble AB Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624 [TBL] [Abstract][Full Text] [Related]
16. Pyrrolo[2,1-c][1,4]benzodiazepine-beta-glucuronide prodrugs with a potential for selective therapy of solid tumors by PMT and ADEPT strategies. Kamal A; Tekumalla V; Raju P; Naidu VG; Diwan PV; Sistla R Bioorg Med Chem Lett; 2008 Jul; 18(13):3769-73. PubMed ID: 18538566 [TBL] [Abstract][Full Text] [Related]
18. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823 [TBL] [Abstract][Full Text] [Related]
19. In vivo synthesis of triple-loaded albumin conjugate for efficient targeted cancer chemotherapy. Châtre R; Lange J; Péraudeau E; Poinot P; Lerondel S; Le Pape A; Clarhaut J; Renoux B; Papot S J Control Release; 2020 Nov; 327():19-25. PubMed ID: 32777236 [TBL] [Abstract][Full Text] [Related]
20. Glucuronides in anti-cancer therapy. Chen X; Wu B; Wang PG Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]